Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients

Soon Jun Hong, Seung Cheol Choi, Chul Min Ahn, Jae Hyung Park, Jae Sang Kim, Do-Sun Lim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Telmisartan is a peroxisome proliferator-activated receptor-γ activator with potent anti-inflammatory and antiatherogenic effects. The authors compared the effects of telmisartan and valsartan on neointima volume, atherosclerosis progression and brachial-ankle pulse wave velocity (baPWV) after stenting in hypertensive type 2 diabetes. Design: This was a prospective, randomised, 8-month follow-up study that included patients with significant coronary stenosis who received telmisartan (n=36) or valsartan (n=37). Setting: University hospital. Main outcome measures: Neointima volume and atherosclerosis progression 10 mm proximal and distal to the stented segment were analysed using repeat intravascular ultrasonography. baPWV and inflammatory markers such as interleukin 6, tumour necrosis factor α, C-reactive protein and adiponectin were compared. Results: Neointima volume at 8 months was significantly lower in the telmisartan group than the valsartan group (1.9±1.0 vs 2.6±1.4 mm3/1 mm, p=0.007, respectively). Total plaque volumes 10 mm proximal (7.1±1.5 vs 7.8±1.6 mm3/1 mm, p=0.032, respectively) and distal (3.5±1.4 vs 4.1±1.3 mm3/1 mm, p=0.028, respectively) to the stent were significantly lower in the telmisartan group than the valsartan group at 8 months. The decrease from baseline in baPWV was significantly greater in the telmisartan group than the valsartan group (-52±104 vs 30±113 cm/s, p=0.002, respectively). The increase from baseline in adiponectin levels and the decreases from baseline in interleukin 6 and tumour necrosis factor α levels were significantly greater in the telmisartan group at 8 months. Retinol-binding protein-4, homeostasis model of assessment index, hemoglobin A1c and low-density lipoprotein cholesterol levels decreased significantly in both groups without differences in changes from baseline between the two groups. Conclusions: Telmisartan reduced neointima volume; atherosclerosis progression 10 mm proximal and distal to the stented segment and baPWV independent of blood pressure, glucose and lipid control in hypertensive type 2 diabetes. Clinical trial no: NCT00599885 (clinicaltrials.gov.).

Original languageEnglish
Pages (from-to)1425-1432
Number of pages8
JournalHeart
Volume97
Issue number17
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Valsartan
Neointima
Pulse Wave Analysis
Stents
Ankle
Arm
Atherosclerosis
Adiponectin
Type 2 Diabetes Mellitus
Interleukin-6
Lymphotoxin-beta
Interventional Ultrasonography
Retinol-Binding Proteins
Peroxisome Proliferator-Activated Receptors
telmisartan
zotarolimus
Coronary Stenosis
C-Reactive Protein
LDL Cholesterol
Blood Glucose

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. / Hong, Soon Jun; Choi, Seung Cheol; Ahn, Chul Min; Park, Jae Hyung; Kim, Jae Sang; Lim, Do-Sun.

In: Heart, Vol. 97, No. 17, 01.09.2011, p. 1425-1432.

Research output: Contribution to journalArticle

@article{829975f4ceaf4fad9ac136af31ef662d,
title = "Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients",
abstract = "Objective: Telmisartan is a peroxisome proliferator-activated receptor-γ activator with potent anti-inflammatory and antiatherogenic effects. The authors compared the effects of telmisartan and valsartan on neointima volume, atherosclerosis progression and brachial-ankle pulse wave velocity (baPWV) after stenting in hypertensive type 2 diabetes. Design: This was a prospective, randomised, 8-month follow-up study that included patients with significant coronary stenosis who received telmisartan (n=36) or valsartan (n=37). Setting: University hospital. Main outcome measures: Neointima volume and atherosclerosis progression 10 mm proximal and distal to the stented segment were analysed using repeat intravascular ultrasonography. baPWV and inflammatory markers such as interleukin 6, tumour necrosis factor α, C-reactive protein and adiponectin were compared. Results: Neointima volume at 8 months was significantly lower in the telmisartan group than the valsartan group (1.9±1.0 vs 2.6±1.4 mm3/1 mm, p=0.007, respectively). Total plaque volumes 10 mm proximal (7.1±1.5 vs 7.8±1.6 mm3/1 mm, p=0.032, respectively) and distal (3.5±1.4 vs 4.1±1.3 mm3/1 mm, p=0.028, respectively) to the stent were significantly lower in the telmisartan group than the valsartan group at 8 months. The decrease from baseline in baPWV was significantly greater in the telmisartan group than the valsartan group (-52±104 vs 30±113 cm/s, p=0.002, respectively). The increase from baseline in adiponectin levels and the decreases from baseline in interleukin 6 and tumour necrosis factor α levels were significantly greater in the telmisartan group at 8 months. Retinol-binding protein-4, homeostasis model of assessment index, hemoglobin A1c and low-density lipoprotein cholesterol levels decreased significantly in both groups without differences in changes from baseline between the two groups. Conclusions: Telmisartan reduced neointima volume; atherosclerosis progression 10 mm proximal and distal to the stented segment and baPWV independent of blood pressure, glucose and lipid control in hypertensive type 2 diabetes. Clinical trial no: NCT00599885 (clinicaltrials.gov.).",
author = "Hong, {Soon Jun} and Choi, {Seung Cheol} and Ahn, {Chul Min} and Park, {Jae Hyung} and Kim, {Jae Sang} and Do-Sun Lim",
year = "2011",
month = "9",
day = "1",
doi = "10.1136/hrt.2011.225193",
language = "English",
volume = "97",
pages = "1425--1432",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "17",

}

TY - JOUR

T1 - Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients

AU - Hong, Soon Jun

AU - Choi, Seung Cheol

AU - Ahn, Chul Min

AU - Park, Jae Hyung

AU - Kim, Jae Sang

AU - Lim, Do-Sun

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Objective: Telmisartan is a peroxisome proliferator-activated receptor-γ activator with potent anti-inflammatory and antiatherogenic effects. The authors compared the effects of telmisartan and valsartan on neointima volume, atherosclerosis progression and brachial-ankle pulse wave velocity (baPWV) after stenting in hypertensive type 2 diabetes. Design: This was a prospective, randomised, 8-month follow-up study that included patients with significant coronary stenosis who received telmisartan (n=36) or valsartan (n=37). Setting: University hospital. Main outcome measures: Neointima volume and atherosclerosis progression 10 mm proximal and distal to the stented segment were analysed using repeat intravascular ultrasonography. baPWV and inflammatory markers such as interleukin 6, tumour necrosis factor α, C-reactive protein and adiponectin were compared. Results: Neointima volume at 8 months was significantly lower in the telmisartan group than the valsartan group (1.9±1.0 vs 2.6±1.4 mm3/1 mm, p=0.007, respectively). Total plaque volumes 10 mm proximal (7.1±1.5 vs 7.8±1.6 mm3/1 mm, p=0.032, respectively) and distal (3.5±1.4 vs 4.1±1.3 mm3/1 mm, p=0.028, respectively) to the stent were significantly lower in the telmisartan group than the valsartan group at 8 months. The decrease from baseline in baPWV was significantly greater in the telmisartan group than the valsartan group (-52±104 vs 30±113 cm/s, p=0.002, respectively). The increase from baseline in adiponectin levels and the decreases from baseline in interleukin 6 and tumour necrosis factor α levels were significantly greater in the telmisartan group at 8 months. Retinol-binding protein-4, homeostasis model of assessment index, hemoglobin A1c and low-density lipoprotein cholesterol levels decreased significantly in both groups without differences in changes from baseline between the two groups. Conclusions: Telmisartan reduced neointima volume; atherosclerosis progression 10 mm proximal and distal to the stented segment and baPWV independent of blood pressure, glucose and lipid control in hypertensive type 2 diabetes. Clinical trial no: NCT00599885 (clinicaltrials.gov.).

AB - Objective: Telmisartan is a peroxisome proliferator-activated receptor-γ activator with potent anti-inflammatory and antiatherogenic effects. The authors compared the effects of telmisartan and valsartan on neointima volume, atherosclerosis progression and brachial-ankle pulse wave velocity (baPWV) after stenting in hypertensive type 2 diabetes. Design: This was a prospective, randomised, 8-month follow-up study that included patients with significant coronary stenosis who received telmisartan (n=36) or valsartan (n=37). Setting: University hospital. Main outcome measures: Neointima volume and atherosclerosis progression 10 mm proximal and distal to the stented segment were analysed using repeat intravascular ultrasonography. baPWV and inflammatory markers such as interleukin 6, tumour necrosis factor α, C-reactive protein and adiponectin were compared. Results: Neointima volume at 8 months was significantly lower in the telmisartan group than the valsartan group (1.9±1.0 vs 2.6±1.4 mm3/1 mm, p=0.007, respectively). Total plaque volumes 10 mm proximal (7.1±1.5 vs 7.8±1.6 mm3/1 mm, p=0.032, respectively) and distal (3.5±1.4 vs 4.1±1.3 mm3/1 mm, p=0.028, respectively) to the stent were significantly lower in the telmisartan group than the valsartan group at 8 months. The decrease from baseline in baPWV was significantly greater in the telmisartan group than the valsartan group (-52±104 vs 30±113 cm/s, p=0.002, respectively). The increase from baseline in adiponectin levels and the decreases from baseline in interleukin 6 and tumour necrosis factor α levels were significantly greater in the telmisartan group at 8 months. Retinol-binding protein-4, homeostasis model of assessment index, hemoglobin A1c and low-density lipoprotein cholesterol levels decreased significantly in both groups without differences in changes from baseline between the two groups. Conclusions: Telmisartan reduced neointima volume; atherosclerosis progression 10 mm proximal and distal to the stented segment and baPWV independent of blood pressure, glucose and lipid control in hypertensive type 2 diabetes. Clinical trial no: NCT00599885 (clinicaltrials.gov.).

UR - http://www.scopus.com/inward/record.url?scp=80051550584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051550584&partnerID=8YFLogxK

U2 - 10.1136/hrt.2011.225193

DO - 10.1136/hrt.2011.225193

M3 - Article

VL - 97

SP - 1425

EP - 1432

JO - Heart

JF - Heart

SN - 1355-6037

IS - 17

ER -